Announcement • Jun 04
Coloplast Announces FDA Approval of Titan Prime Inflatable Penile Prosthesis Coloplast announced FDA approval of Titan Prime, an inflatable penile prosthesis (IPP) that represents the company’s next-generation device and will be available in the U.S. in late 2026. Around 30 million men in the US experience ongoing difficulty in getting or keeping an erection firm enough for sexual activity. As an alternative to medication, some benefit from long-term treatment options such as an inflatable penile prosthesis, which is delivered through a single outpatient procedure. Inflatable Penile Prosthesis Titan Prime IPP is designed to emulate the appearance and performance of a natural erection, supporting device performance for patients, surgeons, and partners. Built with proprietary Bioflex – a polymer engineered for greater strength and durability than silicone – Titan Prime IPP delivers greater material strength than leading silicone competitors and withstands higher pressures to reinforce reliability. Titan Prime IPP preserves the rigidity and girth surgeons trust from Titan IPP today, while providing improved flaccid flexibility for comfort and concealability. The result is consistent, predictable outcomes across diverse male anatomies. Titan Prime is now FDA-approved and will be available through a phased launch to urologists and health care systems in the United States beginning in late 2026. Titan Prime IPP is approved for use in the United States by the FDA. Coloplast is pursuing regulatory approvals in other countries, where the product is not yet available. Declared Dividend • May 14
First half dividend of kr.5.00 announced Shareholders will receive a dividend of kr.5.00. Ex-date: 18th May 2026 Payment date: 20th May 2026 Dividend yield will be 14%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not covered by earnings (246% earnings payout ratio). However, it is covered by cash flows (87% cash payout ratio). The dividend has increased by an average of 6.7% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 173% to bring the payout ratio under control. EPS is expected to grow by 91% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio. New Risk • May 13
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.5% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (173% net debt to equity). Dividend is not well covered by earnings (246% payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.5% net profit margin). Reported Earnings • May 13
Second quarter 2026 earnings released: kr.4.31 loss per share (vs kr.4.05 profit in 2Q 2025) Second quarter 2026 results: kr.4.31 loss per share (down from kr.4.05 profit in 2Q 2025). Revenue: kr.7.08b (up 2.2% from 2Q 2025). Net loss: kr.971.0m (down 207% from profit in 2Q 2025). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Announcement • May 13
Coloplast A/S Announces Interim Dividend for the First Half Ended March 31, 2026 Coloplast A/S announced that it will pay a interim dividend of DKK 5.00 per share, for a total dividend pay-out of DKK 1,127 million for the first half ended March 31, 2026. Recent Insider Transactions • Mar 18
Executive VP & CFO recently bought €268k worth of stock On the 10th of March, Anders Lonning-Skovgaard bought around 4k shares on-market at roughly €61.38 per share. This transaction increased Anders' direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months. Announcement • Mar 07
Coloplast A/S Announces President Changes Coloplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April. Announcement • Mar 06
Coloplast A/S Announces CEO Changes Coloplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April. Reported Earnings • Feb 07
First quarter 2026 earnings released: EPS: kr.6.21 (vs kr.4.64 in 1Q 2025) First quarter 2026 results: EPS: kr.6.21 (up from kr.4.64 in 1Q 2025). Revenue: kr.7.04b (flat on 1Q 2025). Net income: kr.1.40b (up 34% from 1Q 2025). Profit margin: 20% (up from 15% in 1Q 2025). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Announcement • Feb 06
Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026 Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies. Announcement • Dec 19
Coloplast A/S Announces Executive Changes Coloplast A/S announced changes to its Executive Leadership Team, affecting the Interventional Urology business and the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group, including Global Operations, Atos, and People & Culture, and in her role in the Executive Leadership Team. An external search is currently on-going to identify a new leader of the global People & Culture function. Dorthe Rønnau will have her last day at Coloplast at the end of February 2026, where Mads Mikkelsen, Vice President, People & Culture, Chronic Care Commercial, will take over the interim leadership of the global People & Culture organisation until a permanent successor has been identified. After more than a decade in Coloplast and more than three decades in the global life science industry, Tommy Johns, Executive Vice President of Interventional Urology, will retire early next year. Tommy Johns has been instrumental in identifying his successor, ensuring a period of overlap between Tommy and his successor to ensure a thorough handover prior to Tommy’s final day with Coloplast early next year. Kevin Hardage will step into the role of Executive Vice President of Interventional Urology. He joins Coloplast on February 9, 2026. Kevin brings extensive experience from the global MedTech industry, including senior leadership experience from Teleflex in the urology space. Declared Dividend • Nov 19
Final dividend of kr.18.00 announced Shareholders will receive a dividend of kr.18.00. Ex-date: 5th December 2025 Payment date: 9th December 2025 Dividend yield will be 24%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not covered by earnings (143% earnings payout ratio) nor is it adequately covered by cash flows (99% cash payout ratio). The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 58% to bring the payout ratio under control. EPS is expected to grow by 53% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio. Board Change • Nov 19
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Annette Bruls was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Oct 09
Coloplast A/S Announces Interim CEO Lars Rasmussen Will Step Down from the Board At the Upcoming Annual General Meeting on December 4, 2025 Coloplast interim CEO Lars Rasmussen has informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. Lars Rasmussen will, as announced earlier this year, continue in the role as interim CEO until a new CEO of Coloplast is in place. Jette Nygaard-Andersen will continue in the role of interim Chair and, together with the Board of Directors, lead Coloplast in the coming period, as the company enters into its next strategic period of long-term, sustainable growth and value creation. Jette Nygaard-Andersen has been a member of the Board since December 2015 and interim Chair since May 5, 2025. The Board of Directors are unanimously supportive of the announced changes. The search for Coloplast’s new CEO is progressing according to plan, and an announcement will follow once a decision has been made. Announcement • Oct 01
Coloplast A/S, Annual General Meeting, Dec 03, 2026 Coloplast A/S, Annual General Meeting, Dec 03, 2026. Reported Earnings • Aug 19
Third quarter 2025 earnings released: EPS: kr.3.57 (vs kr.5.67 in 3Q 2024) Third quarter 2025 results: EPS: kr.3.57 (down from kr.5.67 in 3Q 2024). Revenue: kr.6.96b (up 1.1% from 3Q 2024). Net income: kr.805.0m (down 37% from 3Q 2024). Profit margin: 12% (down from 19% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 07
Second quarter 2025 earnings released: EPS: kr.4.05 (vs kr.5.57 in 2Q 2024) Second quarter 2025 results: EPS: kr.4.05 (down from kr.5.57 in 2Q 2024). Revenue: kr.6.93b (up 5.2% from 2Q 2024). Net income: kr.912.0m (down 27% from 2Q 2024). Profit margin: 13% (down from 19% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 04
First quarter 2025 earnings released: EPS: kr.4.63 (vs kr.5.40 in 1Q 2024) First quarter 2025 results: EPS: kr.4.63 (down from kr.5.40 in 1Q 2024). Revenue: kr.7.03b (up 6.4% from 1Q 2024). Net income: kr.1.04b (down 14% from 1Q 2024). Profit margin: 15% (down from 18% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 6% per year. Announcement • Dec 05
An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B). An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024.
For the period ending September 30, 2024, Coloplast's Skin Care business reported total revenue of DKK 400 million.
An undisclosed buyer completed the acquisition of Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024. Upcoming Dividend • Nov 29
Upcoming dividend of kr.17.00 per share Eligible shareholders must have bought the stock before 06 December 2024. Payment date: 10 December 2024. Payout ratio is on the higher end at 98%, and the cash payout ratio is above 100%. Trailing yield: 2.5%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (1.9%). Announcement • Nov 15
Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy Coloplast A/S announced on 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD) policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision also introduces two separate lists for covered products for DFUs and covered products for VLUs. In addition, the application limit has been expanded from 4 to 8 and the duration of treatment has been increased from 12 to 16 weeks in the final policy. The implementation date of the final policy is set to 12 February 2025. Based on the final evaluation, Kerecis is included on the final list of covered products for DFUs, however, Kerecis has not been included on the covered list for VLUs. Sales related to VLUs in the out-patient setting currently represent a low-single digit portion of the total Kerecis’ sales. Kerecis has an ongoing clinical study on VLUs and will attempt to get coverage for VLUs as soon as the study is completed. Declared Dividend • Nov 07
Final dividend of kr.17.00 announced Shareholders will receive a dividend of kr.17.00. Ex-date: 6th December 2024 Payment date: 10th December 2024 Dividend yield will be 14%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (98% earnings payout ratio) nor is it covered by cash flows (349% cash payout ratio). The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 8.8% to bring the payout ratio under control. EPS is expected to grow by 46% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Announcement • Nov 06
Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025 Coloplast A/S announced that they will report nine months, 2025 results on Aug 19, 2025 Reported Earnings • Nov 05
Full year 2024 earnings released: EPS: kr.22.46 (vs kr.22.21 in FY 2023) Full year 2024 results: EPS: kr.22.46 (up from kr.22.21 in FY 2023). Revenue: kr.27.0b (up 10% from FY 2023). Net income: kr.5.05b (up 5.6% from FY 2023). Profit margin: 19% (in line with FY 2023). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Sep 27
Coloplast A/S, Annual General Meeting, Dec 04, 2025 Coloplast A/S, Annual General Meeting, Dec 04, 2025. Reported Earnings • Aug 21
Third quarter 2024 earnings released: EPS: kr.5.67 (vs kr.5.99 in 3Q 2023) Third quarter 2024 results: EPS: kr.5.67. Revenue: kr.6.89b (up 13% from 3Q 2023). Net income: kr.1.27b (flat on 3Q 2023). Profit margin: 19% (down from 21% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Announcement • Aug 20
Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24 Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%. Declared Dividend • May 09
First half dividend of kr.5.00 announced Shareholders will receive a dividend of kr.5.00. Ex-date: 13th May 2024 Payment date: 15th May 2024 Dividend yield will be 6.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (94% earnings payout ratio) nor is it covered by cash flows (448% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 4.1% to bring the payout ratio under control. EPS is expected to grow by 43% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Reported Earnings • May 07
Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023) Second quarter 2024 results: EPS: kr.5.57 (up from kr.5.44 in 2Q 2023). Revenue: kr.6.59b (up 8.7% from 2Q 2023). Net income: kr.1.25b (up 8.4% from 2Q 2023). Profit margin: 19% (in line with 2Q 2023). Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 4% per year. Reported Earnings • Feb 11
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr.6.61b (up 8.2% from 1Q 2023). Net income: kr.1.21b (up 7.5% from 1Q 2023). Profit margin: 18% (in line with 1Q 2023). Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Announcement • Feb 01
Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US Coloplast A/S aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. Changing demographics and an aging population are leading to a higher demand for healthcare services, putting significant strain on healthcare systems. In the US, chronic wounds are reported to affect 10.5 million patients annually1, while 2.5 million patients develop a pressure injury in acute care facilities each year2. Therefore, it is critical for healthcare providers to choose products that simplify their workflows and deliver the best possible care for their patients. Announcement • Dec 08
Coloplast A/S Approves the Distribution of Year-End Dividend Coloplast A/S approved the distribution of year-end dividend of DKK 16 per share of nominally DKK 1, at the AGM held on December 7, 2023. Buying Opportunity • Nov 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be €118, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings is also forecast to grow by 13% per annum over the same time period. Board Change • Oct 18
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Annette Bruls was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 09
Coloplast A/S, Annual General Meeting, Dec 07, 2023 Coloplast A/S, Annual General Meeting, Dec 07, 2023. 
